Science That Sees Risk Sooner

Kihealth Europe combines advanced biomarker science, high-complexity laboratory testing, and AI-driven analytics to reveal meaningful biological signals before disease becomes harder to change.

The Scientific Opportunity

Disease Begins Before Symptoms Do

Many chronic and complex diseases develop through measurable biological changes long before conventional diagnosis. Kihealth Europe seeks to detect these signals earlier, when intervention may have greater potential.

Early biological change

Cellular injury begins silently at the tissue level.

Detectable biomarker signals

cfDNA methylation and fragmentomic patterns reveal tissue-specific stress.

Rising disease risk

Molecular signal accumulates before clinical thresholds are crossed.

Clinical symptoms

Conventional signs appear after substantial biological change has occurred.

Diagnosis

Standard diagnosis often comes late in the disease continuum.

Research & Scientific Collaboration

Advancing the Science Through Collaboration

Kihealth Europe advances the science behind InterceptIQ™ through active collaboration with leading academic institutions, clinical research organizations, healthcare systems, biobanks, pharmaceutical and biotechnology companies, diagnostic developers, and patient and research networks. These partnerships shape our development programmes, expand evidence generation, and accelerate the translation of biological insight into meaningful clinical tools.

Academic institutions

Clinical research organizations

Healthcare systems

Biobanks

Pharmaceutical and biotechnology companies

Diagnostic developers

Patient and research networks

Explore Partnerships & Engagement Models

The Intercept IQ™ Platform

The Platform Connecting Science, Data and Decision-Making

Intercept IQ is the integrated platform that brings together laboratory output, biomarker signal, patient context and algorithmic inference into a single, clinically interpretable workflow.

Laboratory results
Biomarker patterns
Patient and clinical data
Longitudinal changes
Risk-modeling algorithms
Ki Intelligence
Intercept Score outputs

Patient sample

Blood or other biofluid collected in standard clinical settings.

Laboratory analysis

Ultra-deep cfDNA sequencing and methylation profiling.

Biomarker data

Tissue-specific methylation and fragmentomic signatures.

Ki Intelligence

Integrated data layer combining clinical and biomarker inputs.

Risk model

Machine-learned inference calibrated to disease biology.

Intercept Score

A standardised output quantifying biological activity.

Clinical insight

Actionable information for physicians and researchers.

The Intelligence Engine Behind the Platform

Ki Intelligence analyzes multiple data points together rather than interpreting each biomarker in isolation. By integrating biomarker signal, clinical context and longitudinal measurements, it is designed to help surface meaningful biological patterns and support more informed clinical interpretation.

Pattern recognition

Detects coordinated biomarker signatures across multiple molecular and clinical dimensions to surface biologically relevant signals.

Risk stratification

Combines patient, laboratory and longitudinal data to help distinguish levels of biological activity and support prioritisation.

Multivariable modeling

Integrates many variables at once rather than relying on single-biomarker thresholds, improving robustness and context.

Longitudinal monitoring

Tracks how signals change over time, enabling comparison of new results against an individual's historical profile.

Model refinement

Continuously validated against emerging data to improve calibration, reliability and interpretability.

Population-level research

Informs broader research into disease biology and biomarker performance across diverse groups and clinical settings.

Future diagnostic applications

Designed to support the development of new analytical products intended for clinical and research use.

The Kihealth Workflow

From blood sample to biological insight

Every Kihealth result is powered by advanced molecular biology, precision laboratory workflows and proprietary analytical processes — engineered to transform a single tube of blood into actionable clinical intelligence.

Phase 01 / 10Channel 01/10

Patient Blood Collection

A blood sample is collected using specialized collection technology designed to preserve cell-free DNA and maintain sample integrity throughout transportation and processing.

Patient

Blood Draw

Norgen Tube

Volume

10 mL

Temp

4.2 °C

Active phaseStep 1 of 10

Risk Modeling & the Intercept Score

Turning Complex Data Into a Clearer Understanding of Risk

Kihealth's risk-modeling approach is designed to translate diverse biological and clinical inputs into a structured, interpretable assessment. Each step is quality-controlled and intended to support more informed clinical decision-making.

Models are evaluated and validated for their intended populations and uses.

01
Input collection
Relevant biological and clinical inputs are collected.
02
Standardization & QC
The data are standardized and quality checked.
03
Ki Intelligence evaluation
Ki Intelligence evaluates relationships across the data.
04
Structured risk assessment
Validated risk models generate a structured risk assessment.
05
Intercept Score output
The Intercept Score presents the result in an interpretable format.
06
Longitudinal insight
Future testing can show whether risk patterns are changing over time.

The Big Takeaway

Transforming a Blood Sample Into Actionable Health Intelligence

A blood sample contains thousands of biological signals. KiHealth Europe combines advanced laboratory testing with the Intercept IQ™ platform and Ki Intelligence to translate those complex signals into a clearer understanding of health and disease risk.

Collect

A patient blood sample is collected using standardized protocols.

Measure

The laboratory analyzes selected biomarkers associated with metabolic health, inflammation, immune activity, and disease development.

Integrate

Intercept IQ brings the laboratory results together with relevant clinical, demographic, and longitudinal data.

Interpret

Ki Intelligence evaluates patterns and relationships across the data using validated risk models.

Inform

Complex biological information is translated into an interpretable risk assessment, including the Intercept Score, to support earlier and more informed health decisions.

WORK FLOW

Blood Sample

Biomarker Analysis

Intercept IQ™

Ki Intelligence

Intercept Score

Informed Action

One Sample. Deeper Intelligence. Earlier Opportunity.

The result is more than a laboratory report. It is a dynamic view of biological risk designed to help identify meaningful changes earlier, monitor risk over time, and inform appropriate next steps.

Platform outputs are intended to support—not replace—professional clinical judgment. Specific capabilities and intended uses may vary by test, population, and regulatory status.

The biology behind the disease

Diabetes is, at its core, a story about a single cell type. Each section below unpacks one chapter — the immune attack of Type 1, the metabolic exhaustion of Type 2, the architecture of the islet itself, and the life and death of the beta cell.

Autoimmune disease in which the body's own immune system targets insulin-producing beta cells.
Immune-mediated destruction begins years before clinical symptoms appear.
Disease progresses through defined stages — autoantibody seroconversion (Stage 1), dysglycaemia (Stage 2), clinical onset (Stage 3).
Loss of endogenous insulin production drives lifelong dependence on exogenous insulin.
Clinical progression can be rapid, especially in younger patients — often presenting with diabetic ketoacidosis.

Autoimmune cascade

Type 1 is a story of misdirected immunity — the body learning to attack the very cells that keep it alive.

Why Beta Cells Matter

Beta-cell apoptosis as a measurable biological event

Pancreatic beta cells maintain glucose homeostasis. Increasing evidence suggests that beta-cell injury and apoptosis may begin years before clinical diabetes is diagnosed, releasing tissue-specific cell-free DNA fragments into circulation.

By focusing on biological signals associated with beta-cell health, Kihealth is advancing research being studied to identify earlier indicators of disease activity and progression across the diabetes continuum.

This work reflects Kihealth's broader mission to move healthcare beyond the detection of established disease toward earlier biological insight and more informed clinical decision-making.

Evidence Supporting the Platform

A growing body of peer-reviewed research, conference science and technical documentation underpins the InterceptIQ™ platform and the BetaIntercept™ programmes.

Scientific Posters

Validation and Clinical Application of a ddPCR Unmethylated Insulin cfDNA Methylation Assay.

ADA 2026 Scientific Poster

Research foundation

Foundational peer-reviewed research underlying the platform and BetaIntercept programmes.

Detection of β cell death in diabetes using differentially methylated circulating DNA β Cell death and dysfunction during type 1 diabetes Analysis of B cell death in type 1 diabetes by ddPCR

Conference presentations

Oral and symposium presentations from Kihealth investigators and collaborators.

ADA 2026 deck

Clinical studies

Ongoing and completed clinical study protocols advancing platform validation.

View full list of active studies

Kihealth One Pagers

Download one-page summaries introducing the platform, Type 1 Diabetes research and the BetaIntercept advantage.

The Beta Intercept Advantage Kihealth T1D Accelerating Drug Development

Kihealth white paper

Technical report covering the platform, assay design, performance and validation.

Read full white paper

Two flagship programmes addressing the diabetes continuum

BetaIntercept™ T1

Type 1 Diabetes research

Type 1 Diabetes is characterised by autoimmune-mediated injury of insulin-producing beta cells. BetaIntercept™ T1 is designed to evaluate biomarkers associated with beta-cell injury and loss via cell-free DNA methylation, providing insight being investigated for disease progression and biological activity.

The platform is being studied to support research into disease onset, autoimmune staging, therapeutic response and beta-cell preservation strategies, including the European clinical landscape following recent disease-modifying therapy approvals.

Autoimmune activity

Beta-cell injury

Beta-cell loss

Metabolic dysfunction

BetaIntercept™ T1 is designed to evaluate biological activity associated with earlier stages of this sequence.

BetaIntercept™ T2

Type 2 Diabetes & metabolic health

Type 2 Diabetes develops gradually through interactions between insulin resistance, metabolic stress, low-grade inflammation and beta-cell dysfunction. BetaIntercept™ T2 is a multi-tissue methylation panel being studied alongside traditional metabolic indicators to offer a broader view of disease biology.

This approach is intended to support research into earlier biological changes that may occur before conventional markers indicate significant metabolic impairment, with extensions being investigated for metabolic-associated steatotic liver disease.

Metabolic stress

Insulin resistance

Beta-cell injury

Disease progression being investigated

Review the validation evidence or explore the full European pipeline.

Validation Evidence Programme Pipeline